BH
Therapeutic Areas
Immuneering Pipeline
| Drug | Indication | Phase |
|---|---|---|
| IMM-1-104 | Advanced solid tumors with MAPK pathway mutations | Phase 1/2a |
| IMM-6-415 | Undisclosed oncology target | Discovery |
| Partnered Program A | Undisclosed oncology target | Not Disclosed |
| Partnered Program B | Undisclosed oncology target | Not Disclosed |
Leadership Team at Immuneering
BZ
Ben Zeskind
Co-Founder, President, Chief Executive Officer, Director
MB
Michael Bookman
Chief Legal Officer, Secretary
H'
Harold 'E.B.' Brakewood
Chief Business Officer
CA
Christian Alaia
Senior Director, Financial Planning & Analysis
NA
Naseem Alkaabi
Senior Research Associate
DA
Damaris Arcila
Senior Accountant
HA
Hemalatha Athawale
Senior Research Associate